Evaluation of the Impact of Embryo Biopsy on the Reproductive Potential of Embryos Undergoing In Vitro Fertilization (IVF)
Study Details
Study Description
Brief Summary
To assess the impact of embryo biopsy on the reproductive potential of human embryos.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
This study will recruit patients from the NY/NJ/CT/eastern PA area only.
All patients will undergo an in vitro fertilization (IVF) cycle with hormonal stimulation and an egg retrieval procedure as deemed appropriate for their diagnosis. Following biopsy, the embryos will be transferred. There will be no delay in the time of transfer as no cells will be analyzed prior to transfer.
On day 3 or day 5 of embryo development, all patients will undergo a two (2) embryo transfer. The embryos selected for transfer will be the 2 morphologically best of the embryo cohort. Once selected for transfer, the embryos will be randomized so that one will be biopsied and the other will be transferred without undergoing biopsy. The embryo randomized to biopsy will have a single cell biopsied.
Following delivery, buccal swabs will be collected from infants.
Study Design
Outcome Measures
Primary Outcome Measures
- Impact of biopsy on pregnancy [1 year]
Impact of the biopsy of the embryo on whether a pregnancy is obtained
- Impact of biopsy on delivery [1 year]
Impact of the biopsy on pregnancy resulting in delivery
Eligibility Criteria
Criteria
This study will recruit patients from the NY/NJ/CT/eastern PA area only.
Inclusion Criteria:
-
Maximum of one prior failed IVF treatment cycle
-
Female partner less than 35 years of age
-
Normal day 3 FSH level (<10 miu/mL)
-
Total basal antral follicle count greater than or equal to 12
-
Male partner with greater than 100,000 total motile spermatozoa and at least 1% normal forms
-
Body mass index (BMI) < or = 32
-
Normal uterine cavity
Exclusion Criteria:
-
Diagnosis of chronic anovulation secondary to polycystic ovarian disease
-
Diagnosis of endometrial insufficiency
-
Clinical indication for pre-implantation genetic diagnosis (PGD) (undergoing IVF with PGD to rule out a known genetic defect)
-
Use of testicular aspiration or biopsy procedures to obtain sperm
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Reproductive Medicine Associates of Connecticut | Norfolk | Connecticut | United States | 06850 |
2 | Reproductive Medicine Associates of New Jersey | Morristown | New Jersey | United States | 07960 |
3 | Reproductive Medicine Associates of New York | New York | New Jersey | United States | 10022 |
Sponsors and Collaborators
- Reproductive Medicine Associates of New Jersey
Investigators
- Principal Investigator: Richard T Scott, MD, Reproductive Medicine Associates of New Jersey
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- RMA-00-17